double homeobox 4 like 26 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DUX4L26 profile across patient tissues and cancer cell-line models. DUX4L26 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, DUX4L26 is differentially expressed in 13, with the highest sampling consensus in BRCA. Additionally, DUX4L26 RNA expression shows 13,689 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, BRCA, and THYM as cancer lineages where DUX4L26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUX4L26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUX4L26 survival associations across molecular data types. DUX4L26 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUX4L26 RNA expression–survival associations across cancer types. High DUX4L26 expression shows unfavorable associations in MESO, CESC, READ and BLCA, but favorable associations in UCS and LIHC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for DUX4L26 RNA expression.
This table summarizes DUX4L26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DUX4L26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUX4L26 shows lower tumor expression in BRCA, KICH and UCEC and higher tumor expression in KIRP, KIRC and LUAD. The BRCA box plot shows higher DUX4L26 RNA expression in normal versus tumor tissue (log2 FC = −0.285, t-test p < 0.001).
This table shows molecular features associated with DUX4L26 in patient tissues and cancer cell lines. In patient samples, DUX4L26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
